SEC Form 4 · accession 0001209191-15-072818

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Sep 30, 2015

Accepted (ET)

Oct 1, 2015 · 5:39 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Sep 30, 2015	M	10,400	$35.64	A	355,684	D
Common Stock^F2,F3	Sep 30, 2015	S	3,700	$102.24	D	351,984	D
Common Stock^F2,F4	Sep 30, 2015	S	4,040	$103.20	D	347,944	D
Common Stock^F2,F5	Sep 30, 2015	S	2,260	$104.15	D	345,684	D
Common Stock^F2,F6	Sep 30, 2015	S	400	$105.13	D	345,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$35.64	Sep 30, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	177,600	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $102.24 (range $101.74 to $102.72).
F4Open market sales reported on this line occurred at a weighted average price of $103.20 (range $102.74 to $103.73).
F5Open market sales reported on this line occurred at a weighted average price of $104.15 (range $103.76 to $104.75).
F6Open market sales reported on this line occurred at a weighted average price of $105.13 (range $105.11 to $105.16).
F7Fully vested.